Unknown

Dataset Information

0

Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.


ABSTRACT: Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates. A prospective study of 51 patients less than 30 days of age with severe IH was conducted. All patients were admitted to the hospital for monitoring during initial propranolol treatment at day 0 with dose adjustments at days 7 and 28. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood glucose (BG) levels and potential side effects were evaluated during treatment. There were significant decreases in mean heart rate and SBP after the initiation of propranolol therapy (P??0.05). Bradycardia and hypotension were noted in at least 1 recorded instance in 11.8% and 5.9% of patients, respectively. These hemodynamic changes were not persistent and were asymptomatic. Two patients who had a history of neonatal pneumonia reported severe bronchial hyperreactivity during treatment. This study demonstrated that propranolol administered to properly selected young infants was safe and well tolerated. However, close monitoring should be considered in high-risk young patients.

SUBMITTER: Ji Y 

PROVIDER: S-EPMC5431448 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.

Ji Yi Y   Chen Siyuan S   Xiang Bo B   Yang Yang Y   Qiu Liqing L  

Scientific reports 20170504 1


Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates. A prospective study of 51 patients less than 30 days of age with severe IH was conducted. All patients were admitted to the hospital for monitoring during initial propranolol treatment at day 0 with dose adjustments at days 7 and 28. Heart rate (HR), systolic blood pressure (SBP), diastol  ...[more]

Similar Datasets

| S-EPMC4573957 | biostudies-literature
| S-EPMC4730155 | biostudies-other
| S-EPMC7039967 | biostudies-literature
| S-EPMC5925426 | biostudies-literature
| S-EPMC4134656 | biostudies-literature
| S-EPMC6825155 | biostudies-literature
| S-EPMC9731762 | biostudies-literature
2019-10-04 | GSE138403 | GEO
| S-EPMC7262142 | biostudies-literature
| S-EPMC4128992 | biostudies-literature